AllerGene AI Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

AllerGene AI Therapeutics is a private, preclinical-stage biotech founded in 2020 and based in Boston, MA. The company is developing a novel in vivo CAR-T platform that uses transient mRNA to train the body's T cells to selectively remove mast cells, thereby treating and potentially preventing severe allergic reactions and anaphylaxis. Its approach combines targeted lipid nanoparticle delivery with AI-powered research tools to advance its programs. The company is led by a small team of experienced cell therapy innovators and advisors with deep expertise in immunology and drug development.

Allergic DiseasesImmunology

Technology Platform

In vivo mRNA CAR-T platform using targeted lipid nanoparticles (LNPs) to transiently program a patient's own T cells to eliminate mast cells via apoptosis, aiming to reset the immune system in allergic diseases.

Opportunities

The company targets a massive, underserved market of severe allergic diseases with a potentially curative, one-time therapy.

Success could establish a new therapeutic category and command a high-value premium.

The transient nature of its platform may offer a favorable safety profile compared to permanent gene therapies.

Risk Factors

The technology is novel and unproven, with significant preclinical biological risks including delivery efficiency, target specificity, and long-term immunological effects.

As a first-in-class approach, clinical and regulatory pathways are uncertain.

The company is pre-revenue and reliant on future fundraising.

Competitive Landscape

AllerGene is a first-mover in applying in vivo CAR-T to allergy, but faces indirect competition from companies developing biologic mast cell inhibitors, next-generation allergy immunotherapies, and other gene therapy platforms. Its primary competition is the current standard of care (palliative and desensitization therapies).

More companies in Cell & Gene Therapy →More companies in United States →